Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
about
Genomic profiling in luminal breast cancerDistinct genes related to drug response identified in ER positive and ER negative breast cancer cell linesRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma'Omic approaches to preventing or managing metastatic breast cancerBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerImprovement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.Gene expression profiling of breast cancer.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease.Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsDynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.Genomic index of sensitivity to endocrine therapy for breast cancer.Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnosticsA prognosis classifier for breast cancer based on conserved gene regulation between mammary gland development and tumorigenesis: a multiscale statistical model.The molecular pathology of breast cancer progression.Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreementElevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive valueMicroarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.A clinically relevant gene signature in triple negative and basal-like breast cancerEstrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.DNA methylation profiling reveals a predominant immune component in breast cancers.17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.Signatures of tumor-immune interactions as biomarkers for breast cancer prognosisGenome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development.Practical implications of gene-expression-based assays for breast oncologists.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Breast Cancer Biomarkers: Utility in Clinical Practice.Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.Triple-negative breast cancer--current status and future directions.Molecular basis for therapy resistance.Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?An update on chemotherapy and tumor gene expression profiles in breast cancer.
P2860
Q26862681-0D637998-B6F6-4EEB-B4F2-ED34D7B082B5Q28481323-4E1F8889-FAFC-4FD9-A599-57B5D0AC9A75Q28730529-9F7CCE3F-8304-4AAF-B347-8AC69E35BA36Q28730572-ECC5FD74-FEB4-47CF-A875-764DDAA67C94Q30245184-D168D8D8-1266-4A54-96A0-D7D2F9569C28Q31130084-0FCD9EC3-4F0E-497B-BAFE-0E65C89543FEQ33501853-16A43283-DD69-43AE-978A-43D3A4DE02E4Q33555497-6AD298D7-AFFF-4D0C-BFA4-06FD939E7EC9Q33692020-E43FCC6C-1AAB-4712-A13D-A8EFA0C10B4FQ33698446-C27F1D61-A670-4080-95FC-E7ED2DBE2FBAQ33843830-45CE5019-2482-4FBD-98E9-DDD98857AA93Q33897072-E5579456-6EDF-433E-8BA7-E02F7470AFD4Q33919243-8FA31F2D-B9BF-4728-A7F8-B8D4E66D1910Q34048134-7A6878D6-58E9-44AB-8B1E-4861E04DE251Q34193932-D0707B2B-4A7F-47C1-A080-AC8EF9689CB3Q34275072-19FE6DC1-9C5F-4B92-A54C-E2610E226DEAQ34300562-00BF1BFE-AEB7-413B-888E-8C970B859C77Q34423475-A173533A-4BFD-4D56-B1EA-69BA93911C2DQ34658145-0237780B-F825-42F1-ACE1-7D9138627948Q34752938-EFA120DD-2965-450A-927C-CC62DC198712Q34820314-60DE3B0F-9227-4924-B63A-333A6CCB2589Q35144960-2C777E36-FD95-45CD-BBDA-C1E4A475ECBCQ35450768-795AEC52-8ED1-406D-9812-C7B2C6A08506Q35503492-C0F061BC-3EB9-45B3-90ED-1EC4BEECE805Q35558070-042FB514-BAED-4507-9F01-7731AD63FA6DQ35626576-51127435-AF51-4D55-AB4B-F33EDC20DD69Q35683578-F63AAAD5-D418-4DEC-ABEB-74BAE1E8FEA3Q35909719-13CADC6F-86F0-4BC5-BEB8-8F2743399EB5Q36038847-4D86C372-79A5-47BD-A53C-2E89A99D4B7DQ36230602-09F4EA16-FD5C-415F-B1F1-806DD8DB4897Q36253304-AF5F0E14-CCF8-43E8-8A32-8B85E6162082Q36546754-EDBEF853-177C-4668-AE80-FD4DEF1CD14CQ36989546-3D108D59-8B1C-4E63-9611-93F40044BA27Q37383276-9E50D1A0-15F0-4F32-8C7C-47B21FC727BAQ37441159-254BF711-C614-4130-AE04-D93F9E0C4296Q37534923-EDD39ACD-2BE5-4837-BB53-B2778774182AQ37630082-8117D854-043A-4CC7-A58F-1F7821E17A63Q37751530-9905B275-06C1-4BEC-8BEA-4AEDE9A27082Q37848654-E464F917-53F4-4290-90F3-475CF2A775F5Q38017302-481813F4-9989-4CBB-BDB8-E940E17F0E69
P2860
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genomic grade index is associa ...... n patients with breast cancer.
@en
Genomic grade index is associa ...... n patients with breast cancer.
@nl
type
label
Genomic grade index is associa ...... n patients with breast cancer.
@en
Genomic grade index is associa ...... n patients with breast cancer.
@nl
prefLabel
Genomic grade index is associa ...... n patients with breast cancer.
@en
Genomic grade index is associa ...... n patients with breast cancer.
@nl
P2093
P2860
P50
P356
P1476
Genomic grade index is associa ...... n patients with breast cancer.
@en
P2093
Christos Sotiriou
Cornelia Liedtke
Gabriel N Hortobagyi
Henry Kuerer
Lajos Pusztai
Vicente Valero
William Fraser Symmans
P2860
P304
P356
10.1200/JCO.2008.18.5934
P407
P577
2009-04-13T00:00:00Z